Novartis
995.45
+323.20(+48.08%)
Market Cap₹2,457.85 Cr
PE Ratio25.25
IndustryHealthcare
Company Performance:
1D+48.08%
1M0.00%
6M0.00%
1Y0.00%
5Y+71.91%
View Company Insightsright
More news about Novartis
31Mar 26
Delhi High Court Admits Novartis India's Writ Petition Challenging ₹10.89 Crore DVAT Assessment
Delhi High Court has admitted Novartis India's writ petition challenging a ₹10.89 crore DVAT assessment for AY 2013-14, along with a ₹6.85 crore penalty. The procedural order allows the company to pursue directing tax authorities to complete proceedings within prescribed timelines. A favorable outcome could result in a ₹54.45 lakh refund, while an unfavorable decision would have no financial impact as provisions are already made in the books.
 no imag found
27Mar 26
Novartis India Limited Receives ₹10.28 Crore Income Tax Demand Notice for Assessment Year 2020-21
Novartis India Limited received an income tax demand notice of ₹10,28,40,780 for Assessment Year 2020-21, comprising ₹5,75,85,157 in principal amount and ₹4,52,55,623 in interest. The demand relates to alleged TDS non-compliance regarding margin to stockist and MSME interest payments. The company plans to file an appeal and seek a stay of demand while keeping stock exchanges updated on developments.
 no imag found
27Mar 26
Novartis India Board Approves New Independent Director Appointment
Novartis India Limited's Board meeting on March 27, 2026, resulted in the appointment of Ms. Gowree Gokhale as Additional Non-Executive Independent Director for a 5-year term from April 01, 2026, to March 31, 2031, subject to shareholder approval. Simultaneously, Ms. Sandra Martyres will complete her second and final term as Independent Director on April 18, 2026. The board approved a postal ballot notice for shareholder approval of the new appointment.
 no imag found
06Mar 26
Novartis India Receives Draft Letter of Offer for Open Offer by WaveRise Investments Consortium
Novartis India Limited has received the Draft Letter of Offer dated March 05, 2026, from Axis Capital Limited regarding the open offer by WaveRise Investments Limited consortium. The acquisition involves three primary acquirers - WaveRise Investments Limited, ChrysCapital Fund X, and Two Infinity Partners - along with two persons acting in concert. This follows the public announcement made on February 19, 2026, and represents the next step in the structured acquisition timeline.
 no imag found
26Feb 26
Novartis India Receives Detailed Public Statement for ₹552.49 Crore Open Offer
Novartis India Limited has received the detailed public statement from WaveRise Investments Limited and its consortium partners for their mandatory open offer to acquire 26% voting share capital at ₹860.64 per share. The comprehensive transaction includes underlying share purchase agreement for 70.68% stake acquisition from Novartis AG, with tendering period scheduled from April 21 to May 5, 2026.
 no imag found
20Feb 26
Novartis AG Executes Sale Agreement for 70.68% Stake in Novartis India with Consortium
Novartis AG has formally executed a sale and purchase agreement with a consortium comprising WaveRise Investments Limited, ChrysCapital Fund X, and Two Infinity Partners for the complete divestment of its 70.68% stake in Novartis India Limited. The transaction involves 1,74,50,680 shares with differentiated pricing structures and will result in Novartis AG ceasing to be a promoter while the acquirers gain control and new promoter status, subject to mandatory open offer requirements under SEBI regulations.
 no imag found
28Jan 26
Novartis India Reports 37% Decline in Q3 Net Profit to ₹161 Million
Novartis India Limited posted disappointing third-quarter results with net profit declining 37% to ₹161 million from ₹254 million year-on-year. Revenue also contracted 8% to ₹859 million compared to ₹930 million in the same quarter last year. The results indicate challenging market conditions for the pharmaceutical company's Indian operations.
 no imag found
21Jan 26
Novartis CEO Vas Narasimhan Expects AI Benefits for Pharmaceutical Sector in 7-10 Years
Novartis CEO Vas Narasimhan expects the pharmaceutical sector to see tangible AI benefits within 7-10 years, with the company's Hyderabad facility serving as a key innovation hub. The CEO emphasized cost optimization goals and faster medicine delivery through AI technology, while expressing satisfaction with current workforce levels in India. Narasimhan also highlighted the importance of modernizing India's Ayushman Bharat system for broader patient access and revealed significant investments in neuroscience research targeting conditions like Huntington's, Parkinson's, and Alzheimer's disease.
 no imag found
30Dec 25
Novartis India Board Meeting on January 28, 2026 for Q3FY26 Financial Results
Novartis India Limited has officially announced its Board of Directors meeting scheduled for January 28, 2026, to consider and approve Q3FY26 unaudited financial results. The company has implemented a trading window closure from January 1, 2026, for designated persons in compliance with SEBI regulations, with reopening 48 hours after results declaration.
 no imag found
28Oct 25
Novartis India Reports Robust Q2 Performance with 33% EBITDA Growth
Novartis India Limited announced its Q2 FY2026 financial results, showing significant improvements. Revenue increased by 4% to ₹903.00 crore, EBITDA grew by 33% to ₹239.00 crore, and net profit rose by 19% to ₹242.00 crore. The company's EBITDA margin expanded by 582 basis points to 26.44%. The Board of Directors met on October 28, 2025, to approve these results.
 no imag found
29Jul 25
Novartis India Reports Q1 Results, Appoints Cost Auditors
Novartis India Limited reported Q1 revenue of ₹875.50 crore, down 5.1% year-over-year but up 4.4% quarter-over-quarter. Profit increased 7.3% year-over-year to ₹276.20 crore. The company appointed M/s. D.C. Dave & Co. as Cost Auditors for the upcoming fiscal year, with a remuneration of ₹1.50 lakh plus taxes, subject to shareholder approval via postal ballot.
 no imag found
09May 25
Novartis India Reports Robust Q4 Results, Declares ₹25 Dividend
Novartis India Limited has released its Q4 financial results, showing significant improvements across key metrics. Revenue increased by 3.36% to ₹839.00 crore. EBITDA more than doubled to ₹239.00 crore, with the EBITDA margin expanding to 28.49%. Net profit surged by 99.59% to ₹293.00 crore. The company's board has recommended a dividend of ₹25.00 per equity share.
 no imag found
Novartis
995.45
+323.20
(+48.08%)
1 Year Returns:0.00%
Industry Peers
Sun Pharmaceutical
1,668.60
(-0.41%)
Divis Laboratories
6,280.00
(+0.82%)
Torrent Pharmaceuticals
4,191.20
(+0.28%)
Lupin
2,328.70
(+0.11%)
Dr Reddys Laboratories
1,232.60
(-0.25%)
Cipla
1,229.50
(-0.91%)
Zydus Life Science
936.50
(-0.79%)
Mankind Pharma
2,144.00
(+0.89%)
Aurobindo Pharma
1,367.80
(-1.31%)
Alkem Laboratories
5,642.00
(+1.07%)